<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

Similarly, in an exploratory analysis that was conducted in a cohort of patients included in a molecular screening program at the MD Anderson Cancer Center, the presence of HER-2 amplification/overexpression was associated with decreased OS, although these results did not reach statistical significance. 25 In a retrospective study by Sartore-Bianchi and colleagues, no difference in survival was observed between HER-2-positive and -negative tumors. 26 However, it should be considered that in this study 64% of HER-2-positive patients received anti-HER-2-targeted therapies within the HERACLES A and

also in 111,027 other papers